Artios Alternatives & Competitors
12 companies similar to Artios — Taking control of the DNA Damage Response (DDR)
Pheon Therapeutics
Pheon is an Antibody-Drug Conjugate specialist developing next generation ADCs for a range...
London, United Kingdom
T-knife Therapeutics
T-knife uses a mouse platform to create human TCRs for cancer treatment without modificati...
San Francisco, United Sta...
ITM Isotope Technologies Munich SE
Delivering the promise of radiopharmaceuticals to patients.
Germany
T-Therapeutics Ltd
Making T-Cell Receptor Biologics a Reality
Cambridge, United Kingdom
Track all Artios competitors
Get real-time alerts when any of these companies raise funding, hire, or show growth signals.
PhotonPharma
An immuno-oncology company unleashing the body to fight cancer
Fort Collins, United Stat...
Brenus Pharma
Next-generation cancer treatment bringing the immune system one step ahead of cancer 🧬🟣
Lyon, France
Focal Medical, Inc. (acquired by Continuity Biosciences)
We are developing novel targeted therapeutic products based on our innovative local drug-d...
Cary, United States
Pear Bio
Patient-centered cancer precision medicine
London, United Kingdom
Affini-T Therapeutics
Right Targets. Right Cells. Right Place. Unlocking the power of T cells against oncogenic...
Watertown, United States
TScan Therapeutics
Unleash Immunity
Waltham, United States
Imuno Therapeutics
Identifying true targets in oncology and autoimmune disorders
Leiden, The Netherlands
Incyclix Bio
Regaining Cell Cycle Control
Durham, United States
About Artios
Taking control of the DNA Damage Response (DDR)
Development of DDR-based cancer treatments, Clinical research and trials, Drug discovery and development, Innovative cancer therapeutic pipelines
Patients with hard-to-treat solid tumors, Oncologists and cancer treatment centers, Pharmaceutical partnerships, Biotechnology researchers
DNA Damage Response, Cancer Treatment, Drug Discovery, DDR Pathways, ATR Inhibitor, Polθ Inhibitor, Oncology Drug Pipeline, Research Collaboration, Solid Tumour Indications, Monotherapy, Combination Treatments, Cancer Research, Novel Therapies, Biopharmaceutical
B2B, B2D
Licensing, Performance Based, Project Based
Frequently Asked Questions
Don't just read about them. Follow them.
BounceWatch watches Artios and millions of other companies. When one raises money, hires quickly or changes its product, we tell you the same day.
Compiled from the BounceWatch company index. We last looked at Artios on 2 Sep 2026. The 12 companies listed here were last checked between 17 Sep 2025 and 15 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.
